Global investment firm Blackstone has announced the acquisition of AYUMI Pharmaceutical, a leading Japanese specialty pharma company, marking its first controlling private equity investment in Japan. The deal was made through Blackstone-managed private equity funds, though the purchase price remains undisclosed.

Blackstone’s Strategic Move into Japan’s Pharma Sector

Blackstone’s acquisition of AYUMI Pharmaceutical represents a significant step into Japan’s thriving pharmaceutical market. AYUMI, founded in 2015, has carved a niche in the treatment of rheumatoid arthritis (RA) and orthopedic disorders. The company was formed through the merger of Santen Pharmaceutical’s anti-rheumatic drug business and Showa Yakuhin Kako’s medical business, quickly establishing itself as a leader in its field.

Expert Leadership and Global Expansion Goals

The acquisition signals Blackstone’s confidence in AYUMI’s seasoned management team. Atsuhiko Sakamoto, Senior Managing Director and Head of Japan Private Equity at Blackstone, emphasized the company’s strong foundation and its expertise in RA and orthopedics. He expressed optimism about leveraging Blackstone’s global resources to further AYUMI’s growth, particularly in advancing innovative treatments and expanding its product portfolio to meet rising market demands.

“Under the leadership of its seasoned management team, AYUMI has established a robust foundation as a leading specialty pharmaceutical company in the field of rheumatism and orthopedics,” said Sakamoto. He further highlighted the company’s world-class medical and scientific capabilities, noting the growing global need for AYUMI’s products.

Key Products and Market Leadership

AYUMI Pharmaceutical’s flagship product, Calonal, is Japan’s top-selling prescription acetaminophen drug, and its RA portfolio includes cutting-edge treatments that are pivotal at every stage of RA diagnosis. These high-demand treatments are part of AYUMI’s strategy to expand its leadership in the market.

Growth and Future Expectations

Ouchi Hikaru, President and CEO of AYUMI, expressed enthusiasm for the new partnership with Blackstone, acknowledging the company’s strong growth platform under previous partner Unison Capital. However, he stressed the need for additional investment to continue expanding AYUMI’s presence, particularly in biosimilars and orthopedic treatments. Hikaru voiced confidence that Blackstone’s involvement would accelerate the company’s growth and enhance its position in the Japanese pharmaceutical industry, benefiting patients and society alike.

Looking Ahead: Completion and Impact

The acquisition, subject to regulatory approvals and customary closing conditions, is expected to conclude by Q2 2019. With Blackstone’s deep financial resources and global footprint, AYUMI Pharmaceutical is set to strengthen its market position, offering advanced solutions in rheumatoid arthritis and orthopedics, and contributing further to global healthcare innovations.

  Atsuhiko Sakamoto, AYUMI Pharmaceutical, Blackstone, Calonal, Japan, M3, Ouchi Hikaru, Pharmaceutical Industry, Rheumatoid arthritis, Unison Capital